Top Markets
#1 Black Phoenix Black Phoenix +366.91%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.04%
#4 Akedo Akedo +54.95%
#5 Acurast Acurast +36.49%
#6 BasedHype BasedHype +30.05%
#7 Avantis Avantis +25.87%
#8 Cryptopia Cryptopia +22.42%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.61%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.15%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Kadimastem Ltd Kadimastem Ltd

Kadimastem Ltd

KDST
Rank in Stocks #41016
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Share Price
$12.16
Last synced: 2025-10-30
Market Cap
$50.98K
Change (1 day)
-0.10%
Change (1 year)
56.95%
Country
IL
Trade Kadimastem Ltd (KDST)

Category

Healthcare
P/E ratio for Kadimastem Ltd (KDST)
P/E ratio as of 2026 TTM: 0
According to Kadimastem Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Kadimastem Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.